Mining and analysis of the ADE signals of avapritinib based on FAERS database

HU Ying; LI Jianping; TANG Bin; DING Qiao

doi:10.6039/j.issn.1001-0408.2023.13.15

您当前的位置：

首页 >

文章列表页 >

Mining and analysis of the ADE signals of avapritinib based on FAERS database

更新时间：2023-08-15

- Mining and analysis of the ADE signals of avapritinib based on FAERS database
- ZHONGGUO YAOFANG Vol. 34, Issue 13, Pages: 1622-1626(2023)
- 作者机构：
  
  遵义医科大学第三附属医院/遵义市第一人民医院神经重症医学科，贵州遵义　563000
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.13.15
  CLC： R969.3;R979.1
- Published：15 July 2023，
  
  Received：24 November 2022，
  
  Revised：19 June 2023，
扫描看全文
胡颖,李建萍,唐斌等.基于美国FAERS数据库挖掘与分析阿伐替尼ADE信号 ^Δ[J].中国药房,2023,34(13):1622-1626.

HU Ying,LI Jianping,TANG Bin,et al.Mining and analysis of the ADE signals of avapritinib based on FAERS database[J].ZHONGGUO YAOFANG,2023,34(13):1622-1626.
胡颖,李建萍,唐斌等.基于美国FAERS数据库挖掘与分析阿伐替尼ADE信号 ^Δ[J].中国药房,2023,34(13):1622-1626. DOI： 10.6039/j.issn.1001-0408.2023.13.15.

HU Ying,LI Jianping,TANG Bin,et al.Mining and analysis of the ADE signals of avapritinib based on FAERS database[J].ZHONGGUO YAOFANG,2023,34(13):1622-1626. DOI： 10.6039/j.issn.1001-0408.2023.13.15.

摘要

目的

为阿伐替尼的临床安全应用提供参考。

方法

从美国FAERS数据库收集2020年1月9日至2022年9月30日关于阿伐替尼的药品不良事件（ADE）报告，采用比例失衡法中的报告比值比法和比例报告比法进行数据挖掘与分析。

结果

共收集到以阿伐替尼为首要怀疑药物的ADE报告10 895份，排除无效信号后得到201个ADE信号，涉及19个系统器官分类。耳鸣、痴呆、四肢厥冷、血铁减少、血糖下降、发热、维生素D下降、维生素B

下降等ADE，以及肌肉骨骼及结缔组织疾病、生殖系统及乳腺疾病这2个SOC中的所有ADE均未被该药的药品说明书收载。用药信息完整的ADE报告有670份，以神经系统（230份，占34.33%）和眼器官（277份，占41.34%）的ADE报告占比较大。与其他系统相比，日剂量和用药疗程对神经系统及眼器官ADE的影响显著（

＜0.05），患者年龄对神经系统ADE的影响显著（

＜0.05）。

结论

年龄≥65岁、日剂量300 mg/d、用药疗程31～90 d的患者使用阿伐替尼后发生神经系统ADE的风险较高；而日剂量300 mg/d、用药疗程31～90 d的患者还容易发生眼器官ADE。临床在使用阿伐替尼过程中，应重点关注患者眼部、神经系统方面的异常表现，并及时予以干预。

Abstract

OBJECTIVE

To provide reference for clinically safe application of avapritinib.

METHODS

The adverse drug event （ADE） reports of avapritinib from January 9th，2020，to September 30th，2022 were collected from FDA Adverse Event Reporting System （FAERS） database. For data mining and analysis，reporting odds ratio （ROR） method and proportional reporting ratio （PRR） method in the proportional imbalance method were utilized.

RESULTS

A total of 10 895 ADE reports with avapritinib as the main suspect drug were gathered，and 201 ADE signals involving 19 systematic organ classifications were found after eliminating invalid signals. The instruction of the drugs did not mention any of the ADE，including tinnitus，dementia，chilly limbs，the reduction of blood iron，the reduction of blood sugar，fever，the reduction of vitamin D and vitamin B

，as well as all ADE in the 2 SOCs of musculoskeletal and connective tissue illnesses，diseases of the reproductive system，and diseases of the breast. The majority of the ADE reports 670 cases with complete drug information were for the nervous system （230 cases，accounting for 34.33%） and ocular organ （277 cases，accounting for 41.34%）. Compared with other systems，daily dose and treatment course showed significant effects on ADE of neurological system and ocular organ （

＜0.05），and the patient’s age had a significant impact on the ADE of the nervous system （

＜0.05）.

CONCLUSIONS

A greater incidence of ADE after using avapritinib is present in patients older than 65 with a daily dose of 300 mg/d and a treatment period lasting between 31 and 90 days； patients receiving a daily dose of 300 mg/d and a treatment regimen lasting 31 to 90 days are more likely to experience ADE of the ocular organ. Attention should be given to the aberrant symptoms of the patient’s eyes and nervous system throughout clinical use of avapritinib，and prompt intervention should be given.

关键词

阿伐替尼药品不良事件比例失衡法信号挖掘药物不良反应

Keywords

adverse drug eventproportional imbalance methodsignal miningadverse drug reaction

references

SERRANO C. New treatments in advanced gastrointestinal stromal tumor[J]. Curr Opin Oncol，2021，33（4）：323-328.

SHARMA A K，KIM T S，BAUER S，et al. Gastrointestinal stromal tumor：new insights for a multimodal approach[J]. Surg Oncol Clin N Am，2022，31（3）：431-446.

FERNÁNDEZ J A，FERRERAS D，RUIZ-MANZANERA J J，et al. Characteristics and prognosis of jejunoileal ga- strointestinal stromal tumours （GISTs） in the era of imatinib：a comparative study with gastric GISTs[J]. Clin Transl Oncol，2021，23（7）：1368-1376.

SHI H P，WANG Z Q，FAN Z Y，et al. Analysis and comparison of the clinical features and prognosis between extra-gastrointestinal stromal tumors and duodenal gastrointestinal stromal tumors[J]. Chin J Gastrointest Surg，2019，22（9）：856-860.

BAUER S，GEORGE S，VON MEHREN M，et al. Early and next-generation KIT/PDGFRA kinase inhibitors and the future of treatment for advanced gastrointestinal stromal tumor[J]. Front Oncol，2021，11：672500.

ALZOFON N，JIMENO A. Avapritinib for metastatic or unresectable gastrointestinal stromal tumors[J]. Drugs Today，2020，56（9）：561-571.

中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会（CSCO）胃肠间质瘤诊疗指南2021[M]. 北京：人民卫生出版社，2021：64.

DEANGELO D J，RADIA D H，GEORGE T I，et al. Safety and efficacy of avapritinib in advanced systemic mastocytosis：the phase 1 EXPLORER trial[J]. Nat Med，2021，27（12）：2183-2191.

张科，邵佳，孙璇，等. 基于FAERS的二肽基肽酶4抑制剂相关不良事件信号挖掘[J]. 中国药房，2022，33（24）：3015-3019.

司方莹，薛莹，卢晓静，等. 基于真实世界对托法替布上市后不良事件信号的挖掘与分析[J]. 中国医院药学杂志，2022，42（22）：2407-2410，2420.

JONES R L，SERRANO C，VON MEHREN M，et al. Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours：long-term efficacy and safety data from the NAVIGATOR phase Ⅰ trial[J]. Eur J Cancer，2021，145：132-142.

JOSEPH C P，ABARICIA S N，ANGELIS M A，et al. Optimal avapritinib treatment strategies for patients with metastatic or unresectable gastrointestinal stromal tumors[J]. Oncologist，2021，26（4）：e622-e631.

HEINRICH M C，JONES R L，VON MEHREN M，et al. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour （NAVIGATOR）：a multicentre，open-label，phase 1 trial[J]. Lancet Oncol，2020，21（7）：935-946.

BENSON A B，VENOOK A P，AL-HAWARY M M，et al. Colon cancer，version 2.2021，NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw，2021，19（3）：329-359.

WANG T，ZENG X Y，YANG W C，et al. Clinicopathological characteristics and prognosis of patients with sporadic multiple primary gastrointestinal stromal tumors[J]. Chin J Gastrointest Surg，2021，24（9）：783-788.

BELOW S，MICHAELIS L C. Avapritinib in the treatment of systemic mastocytosis：an update[J]. Curr Hematol Malig Rep，2021，16（5）：464-472.

GOTLIB J，REITER A，RADIA D H，et al. Efficacy and safety of avapritinib in advanced systemic mastocytosis：interim analysis of the phase 2 PATHFINDER trial[J]. Nat Med，2021，27（12）：2192-2199.

DHILLON S. Avapritinib：first approval[J]. Drugs，2020，80（4）：433-439.

VALENT P，AKIN C，HARTMANN K，et al. Updated diagnostic criteria and classification of mast cell disorders：a consensus proposal[J]. Hemasphere，2021，5（11）：e646.

REITER A，SCHWAAB J，DEANGELO D J，et al. Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis[J]. Blood Adv，2022，6（21）：5750-5762.

KANG Y K，GEORGE S，JONES R L，et al. Avapritinib versus regorafenib in locally advanced unresectable or metastatic GI stromal tumor：a randomized，open-label phase Ⅲ study[J]. J Clin Oncol，2021，39（28）：3128-3139.

GARCÍA CARIDE S，MARQUINA G，DÍAZ VALLE D. Preseptal cellulitis，intraocular inflammatory reaction and corneal persistent epithelial defect as side effects of avapritinib[J]. Anticancer Drugs，2021，32（10）：1127-1130.

HENRIQUES-ABREU M，SERRANO C. Avapritinib in unresectable or metastatic gastrointestinal stromal tumor with PDGFRA exon 18 mutation：safety and efficacy[J]. Expert Rev Anticancer Ther，2021，21（10）：1081-1088.

MAZZOCCA A，NAPOLITANO A，SILLETTA M，et al. New frontiers in the medical management of gastrointestinal stromal tumours[J]. Ther Adv Med Oncol，2019，11：1758835919841946.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Case analysis of a patient with isavuconazonium-caused pancytopenia

Signals mining and analysis of adverse drug events of pazopanib based on FAERS database

我院776例药品不良反应报告分析

复方苦参注射液对胃癌患者化疗药物不良反应的影响

Evidence-based Pharmaceutical Practice Responding for Novel Coronavirus Pneumonia Epidemic

Related Author

LIU Xiaoping

LIN Xiaolu

LI Jianfang

BO Mingming

SHI Yafei

SUN Jixiong

WANG Tianyu

LI Guohui

Related Institution

Dept. of Pharmacy， Guangzhou Development District Hospital

Dept. of Pharmacy， Sun Yat-sen Memorial Hospital， Sun Yat-sen University

Dept. of Pharmacy， National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital， Chinese Academy of Medical Sciences and Peking Union Medical College

Dept. of Pharmacy， Langfang Branch， National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital， Chinese Academy of Medical Sciences

Information Management Center， Langfang Branch， National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital， Chinese Academy of Medical Sciences

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰